Follow us on Twitter
Below you will find current and archived press releases for your associated company. Navigate by selecting the year in the list below and click on the press release you want to read. Distribution takes place with a maximum of five minutes delay from press release.
In connection with the BioStock Investor Meeting in Stockholm, BioStock's reporter was visited by Anders Svensson, CFO of OssDsign. Svensson told ...
Uppsala, 26 september 2022. OssDsign AB (publ.) meddelar idag att en oberoende klinisk forskargrupp i New York, USA, ledd av Ralph Rahme, har publ...
Medtech company OssDsign develops and manufactures regenerative implants and patient-specific solutions for the treatment of bone defects. CFO And...
OssDsign AB (publ) announces that the interim report for Q2 2022 is now available as a pdf on the company's website www.ossdsign.com. A pdf versio...
Uppsala, 21 juni 2022. OssDsign AB (publ.) meddelar idag att bolaget har sålt de första exemplaren av sitt kranialimplantat OssDsign Cranial PSI i...
Uppsala, 13 juni 2022. OssDsign AB (publ.) meddelar idag att de första 100 patienterna har behandlats med bolagets innovativa syntetiska bengraft ...
Uppsala, 8 juni, 2022. OssDsign AB (publ.) meddelar idag att man har engagerat Skandinaviska Enskilda Banken (publ) (SEB) för att producera löpand...
Uppsala, 7 juni 2022. OssDsign AB (publ.) meddelar idag att bolaget har etablerat en strategisk Advisory Board (SSAB) i USA. Dess primära målsättn...
Today, the annual general meeting of 2022 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeti...
OssDsign AB (publ) announces that the interim report for Q1 2022 is now available as a pdf on the company's website www.ossdsign.com. A pdf versio...
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 a.m. on Wednesday 1 J...
OssDsign AB (publ) announces that the Annual Report for 2021 is now available as a pdf on the company's website www.ossdsign.com. A pdf version is...
Uppsala, 25 april 2022. OssDsign AB (publ.) meddelar idag att bolaget rekryterat samtliga patienter till den kliniska studien TOP FUSION. Patientu...
Uppsala, 4 april, 2022. OssDsign AB (publ.) meddelar idag att den första patienten har inkluderats i PROPEL, bolagets prospektiva multicenterregis...
Uppsala, 22 mars 2022. OssDsign AB (publ.) meddelar idag att företaget har tecknat ett långtidsavtal för att leverera OssDsign Cranial PSI till Fr...
Another sales record marks the end of a transformative year for OssDsign.
The fourth quarter in figures
Net sales amounted to TSEK 9...
Uppsala, February 7, 2022. OssDsign AB (publ.) today announces that Melanie Marshall has been recruited to a new position as Vice President Clinic...
Uppsala, January 13th, 2022. OssDsign AB (publ.) today announces that the Western Institutional Review Board (WIRB), one of the largest institutio...
